3
On Friday, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released interim data from Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET).
The Independent Data Monitoring Committee (IDMC) recommended stopping the study for futility. The results are unlikely to meet the primary efficacy endpoint.
The committee also indicated that some underlying statistical model assumptions might have influenced this outcome and encouraged Praxis to explore alternative analysis methods.
Also Read: Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
Given the advanced enrollment status for both Study 1 and Study 2 in the Essential3 program and advice received by the IDMC, Praxis has decided to complete both …
